Bupivacaine hydrochloride monohydrate

SKU: orb1944114

Description

Bupivacaine hydrochloride monohydrate is a sodium channel (SCN5A) blocker that also inhibits NMDA receptors and calcium/potassium channels. It is a valuable research tool for studying chronic pain mechanisms in both in vitro electrophysiology and in vivo animal models of neuropathic pain.

Research Area

Metabolism Research, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 73360-54-0
• MW: 342.9
• Purity: 99.91%
• Formula: C₁₈H₃₁ClN₂O₂
• SMILES: Cl.O=C(NC=1C(=CC=CC1C)C)C2N(CCCC)CCCC2.O
• Target: iGluR,Potassium Channel,Sodium Channel,NMDAR,Calcium Channel

Bioactivity

• Target IC50:
  SCN5A channel:2.18±0.16 μM
• In Vitro:
  Bupivacaine hydrochloride monohydrate inhibits synaptic transmission mediated by NMDA receptors in the spinal dorsal horn, which is an area closely associated with central sensitization. Bupivacaine hydrochloride monohydrate affects the voltage dependence of channel activation and steady-state inactivation by shifting the half-maximal activation/inactivation membrane potential to a slightly more negative membrane potential.In the inactivated state, the SCN5A channel shows slight sensitivity to Bupivacaine hydrochloride monohydrate (IC50=2.18±0.16 μM). Bupivacaine hydrochloride monohydrate reversibly inhibits SK2 channels in a dose-dependent manner, with an IC50 of 16.5 μM.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NMDA receptor, CalciumChannel, Calcium Channel, SodiumChannel, Sodium Channel, Potassium Channel, PotassiumChannel

Compound Identifiers

PubChem CID

5282419